- Email: [email protected]
Abstract # 3079 Sleep deprivation, inflammation and facial emotion recognition in older adults
e12
Abstracts / Brain, Behavior, and Immunity 76 (2019) e1–e43
astrocytes in conjunction with bTBI to study neuroinflammatory profiles and functional outcomes post-injury. Understanding the molecular and temporal requirements for the negative consequences of IL-1R1 signaling post-injury may lead to therapeutic options for those with TBI. http://dx.doi.org/10.1016/j.bbi.2018.11.207
Abstract # 3079 Sleep deprivation, inflammation and facial emotion recognition in older adults Dominique Piber a,b, Naomi I. Eisenberger c, Richard Olmstead a, Joshua Hyong-Jin Cho a, Teresa E. Seeman d, Elizabeth C. Breen a, Steve W. Cole a, Ellora Karmarkar a, Nina Sadeghi a, Michael R. Irwin a a
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, United States b Department of Psychiatry, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Germany c Department of Psychology, College of Arts and Sciences, University of California, Los Angeles, United States d Division of Geriatrics, David Geffen School of Medicine, University of California, Los Angeles, United States Background: Sleep disturbance, as well as inflammation predict depression risk, which may be due to effects of sleep loss and/or inflammation on affect regulation. We hypothesized that partial sleep deprivation (PSD) would impair emotion recognition in older adults, and that elevated levels of inflammation would be associated with such changes in affect regulation. Methods: Older adults (N = 39) aged 61–86 years underwent a night of uninterrupted sleep (US), followed by a night of PSD. After each night, an Emotion Recognition Task was administered in a counterbalanced/crossover-design. Morning levels of Toll-like receptor 4 (TLR-4) stimulated monocyte production of interleukin-6 (IL-6) and tumor necrosis factor were measured three times: at baseline prior to the sleep protocol (BL), after US, and after PSD. Results: As compared to US, PSD induced a delay in surprise and fear recognition (p’s < 0.05). Levels of TLR-4 stimulated production of IL-6 at BL (p = 0.04), US (p = 0.03), and PSD (p = 0.07) correlated with PSD-induced delay in fear, but not surprise recognition. Conclusion: Sleep loss induces a delay in surprise and fear recognition in older adults. Pre-existing levels of cellular inflammatory responsivity appear to serve as a vulnerability factor for a delay in fear recognition following sleep loss. These findings have implications for persons with an underlying inflammatory disorder, who may be more at risk for having a failure to recognize salient emotions after sleep curtailment. Support provided by R01AG034588, the Max Kade Foundation, and the Cousins Center for Psychoneuroimmunology. http://dx.doi.org/10.1016/j.bbi.2018.11.208
Abstract # 3080 Tocilizumab, an IL-6 Receptor antagonist, is associated with worse depression, anxiety, pain, and sleep following hematopoietic cell transplantation J.M. Knight a, E.S. Costanzo b, S. Singh a, Z. Yin a, A. Szabo a, C.J. Hillard a, J.D. Rizzo a, C.L. Raison b, A. D’Souza a, C.L. Coe b, W.R. Drobyski a
a Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226, United States b University of Wisconsin-Madison, United States
Sickness symptoms associated with immunomodulatory treatments for cancer provided some of the first evidence for the neural and behavioral actions of cytokines. We now see a reemergence of this clinical relevance in the context of new therapeutic modalities targeting different aspects of immunity, including the IL-6 receptor antagonist tocilizumab. We hypothesized that tocilizumab would decrease depression, anxiety, fatigue, sleep disturbance, and pain in individuals undergoing allogeneic hematopoietic cell transplantation (HCT). This clinical trial compared outcomes from 25 patients receiving pre-HCT tocilizumab to an historical control group of 63 HCT patients. Participants completed self-report measures preHCT, day + 28 (D + 28), D + 100, and D + 180 post-transplant. A linear mixed-effect model co-varying for baseline variables evaluated the effects of tocilizumab on depression, anxiety, fatigue, sleep, and pain. The tocilizumab-exposed group had significantly higher depression scores at D + 28 (p = .02), more anxiety at all time points (p < .05, p = .001, p = .02), more severe pain at D + 28 (p = .01), and worse sleep at day + 28 (p = .04) and D + 180 (p = .02). These unanticipated findings are provocative as achievement of curative regression by novel immunotherapies such as chimeric antigen receptor T cells may be challenged by these undesired behavioral toxicities induced by the administration of immunomodulatory drugs such as tocilizumab. These data challenge the current paradigm of neuroinflammation being the sole mediating pathway to sickness symptoms, somnolence, and pain sensitization and warrant further investigation. http://dx.doi.org/10.1016/j.bbi.2018.11.209
Abstract # 3081 Impaired cognition and fatigue; the role of sleep and neuroinflammation for non-specific symptoms in allergy S. Renberg Tamm a,b, S. Cervenka c, A. Forsberg c, J. Estelius d, J. Grunewald d, P. Gyllfors e, B. Karshikoff a,b,f, E. Kosek a,g, J. Lampa d, C. Lensmar a, V. Strand e, T. Åkerstedt a,b, C. Halldin c, M. Ingvar a, C. Olgart Höglund a,d,h, M. Lekander a,b a Department of Clinical Neuroscience, Karolinska Institutet, Nobels Väg 9, Stockholm 17177, United States b Stress Research Institute, Stockholm University, Stockholm, Sweden c Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden d Department of Medicine and Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden e Asthma & allergy clinic, S:t Görans Hospital, Stockholm, Sweden f Department of Anesthesiology, Perioperative and Pain Medicine, Division of Pain Medicine, Stanford University School of Medicine, Palo Alto, USA g Stockholm Spine Center, Stockholm, Sweden h Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Allergy is associated with non-specific symptoms such as fatigue and impaired cognition. Allergic patients also report worse sleep compared to healthy controls. As part of a study where we investigated seasonal changes in the glial cell marker translocator protein (TSPO), we studied fatigue, sleep and cognitive functions in allergic patients, in relation to seasonal changes in the glial cell marker
Abstracts / Brain, Behavior, and Immunity 76 (2019) e1–e43
astrocytes in conjunction with bTBI to study neuroinflammatory profiles and functional outcomes post-injury. Understanding the molecular and temporal requirements for the negative consequences of IL-1R1 signaling post-injury may lead to therapeutic options for those with TBI. http://dx.doi.org/10.1016/j.bbi.2018.11.207
Abstract # 3079 Sleep deprivation, inflammation and facial emotion recognition in older adults Dominique Piber a,b, Naomi I. Eisenberger c, Richard Olmstead a, Joshua Hyong-Jin Cho a, Teresa E. Seeman d, Elizabeth C. Breen a, Steve W. Cole a, Ellora Karmarkar a, Nina Sadeghi a, Michael R. Irwin a a
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, United States b Department of Psychiatry, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Germany c Department of Psychology, College of Arts and Sciences, University of California, Los Angeles, United States d Division of Geriatrics, David Geffen School of Medicine, University of California, Los Angeles, United States Background: Sleep disturbance, as well as inflammation predict depression risk, which may be due to effects of sleep loss and/or inflammation on affect regulation. We hypothesized that partial sleep deprivation (PSD) would impair emotion recognition in older adults, and that elevated levels of inflammation would be associated with such changes in affect regulation. Methods: Older adults (N = 39) aged 61–86 years underwent a night of uninterrupted sleep (US), followed by a night of PSD. After each night, an Emotion Recognition Task was administered in a counterbalanced/crossover-design. Morning levels of Toll-like receptor 4 (TLR-4) stimulated monocyte production of interleukin-6 (IL-6) and tumor necrosis factor were measured three times: at baseline prior to the sleep protocol (BL), after US, and after PSD. Results: As compared to US, PSD induced a delay in surprise and fear recognition (p’s < 0.05). Levels of TLR-4 stimulated production of IL-6 at BL (p = 0.04), US (p = 0.03), and PSD (p = 0.07) correlated with PSD-induced delay in fear, but not surprise recognition. Conclusion: Sleep loss induces a delay in surprise and fear recognition in older adults. Pre-existing levels of cellular inflammatory responsivity appear to serve as a vulnerability factor for a delay in fear recognition following sleep loss. These findings have implications for persons with an underlying inflammatory disorder, who may be more at risk for having a failure to recognize salient emotions after sleep curtailment. Support provided by R01AG034588, the Max Kade Foundation, and the Cousins Center for Psychoneuroimmunology. http://dx.doi.org/10.1016/j.bbi.2018.11.208
Abstract # 3080 Tocilizumab, an IL-6 Receptor antagonist, is associated with worse depression, anxiety, pain, and sleep following hematopoietic cell transplantation J.M. Knight a, E.S. Costanzo b, S. Singh a, Z. Yin a, A. Szabo a, C.J. Hillard a, J.D. Rizzo a, C.L. Raison b, A. D’Souza a, C.L. Coe b, W.R. Drobyski a
a Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226, United States b University of Wisconsin-Madison, United States
Sickness symptoms associated with immunomodulatory treatments for cancer provided some of the first evidence for the neural and behavioral actions of cytokines. We now see a reemergence of this clinical relevance in the context of new therapeutic modalities targeting different aspects of immunity, including the IL-6 receptor antagonist tocilizumab. We hypothesized that tocilizumab would decrease depression, anxiety, fatigue, sleep disturbance, and pain in individuals undergoing allogeneic hematopoietic cell transplantation (HCT). This clinical trial compared outcomes from 25 patients receiving pre-HCT tocilizumab to an historical control group of 63 HCT patients. Participants completed self-report measures preHCT, day + 28 (D + 28), D + 100, and D + 180 post-transplant. A linear mixed-effect model co-varying for baseline variables evaluated the effects of tocilizumab on depression, anxiety, fatigue, sleep, and pain. The tocilizumab-exposed group had significantly higher depression scores at D + 28 (p = .02), more anxiety at all time points (p < .05, p = .001, p = .02), more severe pain at D + 28 (p = .01), and worse sleep at day + 28 (p = .04) and D + 180 (p = .02). These unanticipated findings are provocative as achievement of curative regression by novel immunotherapies such as chimeric antigen receptor T cells may be challenged by these undesired behavioral toxicities induced by the administration of immunomodulatory drugs such as tocilizumab. These data challenge the current paradigm of neuroinflammation being the sole mediating pathway to sickness symptoms, somnolence, and pain sensitization and warrant further investigation. http://dx.doi.org/10.1016/j.bbi.2018.11.209
Abstract # 3081 Impaired cognition and fatigue; the role of sleep and neuroinflammation for non-specific symptoms in allergy S. Renberg Tamm a,b, S. Cervenka c, A. Forsberg c, J. Estelius d, J. Grunewald d, P. Gyllfors e, B. Karshikoff a,b,f, E. Kosek a,g, J. Lampa d, C. Lensmar a, V. Strand e, T. Åkerstedt a,b, C. Halldin c, M. Ingvar a, C. Olgart Höglund a,d,h, M. Lekander a,b a Department of Clinical Neuroscience, Karolinska Institutet, Nobels Väg 9, Stockholm 17177, United States b Stress Research Institute, Stockholm University, Stockholm, Sweden c Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden d Department of Medicine and Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden e Asthma & allergy clinic, S:t Görans Hospital, Stockholm, Sweden f Department of Anesthesiology, Perioperative and Pain Medicine, Division of Pain Medicine, Stanford University School of Medicine, Palo Alto, USA g Stockholm Spine Center, Stockholm, Sweden h Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Allergy is associated with non-specific symptoms such as fatigue and impaired cognition. Allergic patients also report worse sleep compared to healthy controls. As part of a study where we investigated seasonal changes in the glial cell marker translocator protein (TSPO), we studied fatigue, sleep and cognitive functions in allergic patients, in relation to seasonal changes in the glial cell marker